医学
血管舒缩
透皮
内科学
内分泌学
骨质疏松症
更年期
雌激素
激素疗法
内分泌系统
激素
疾病
激素替代疗法(女性对男性)
加药
临床试验
心血管健康
血脂谱
血脂
热闪光
雌激素疗法
性激素结合球蛋白
作者
Paul Charles M. Piette,James A. Simon
标识
DOI:10.1080/09513590.2026.2694742
摘要
Objective Identify estradiol serum levels associated with vasomotor symptom relief and assess their effects on osteoporosis and cardiovascular prevention using an estradiol hydro-alcoholic gel formulation.Methods Estradiol serum concentrations from two pivotal efficacy and safety trials with transdermal (TdL) estradiol gel were compared to those reported in the KEEPS and ELITE trials regarding skeletal and cardiovascular disease prevention.Results A total of 567 patients were included in the intent-to-treat efficacy population. In the first study (n = 216), the daily 2.5 g dose of TdL E2 gel reduced the moderate to severe hot flash frequency from a baseline of 10.5 to 2.0 ± 4.2 (−82%). In the second study (n = 351), a daily 2.5 g dose of TdL E2 gel reduced moderate-to-severe hot flushes from 11.8 to 2.3 ± 3.8, similar to the TdL E2 patch, which decreased them from 10.9 to 1.3 ± 3.2. The serum concentrations of E2 from patients receiving the TdL E2 gel once daily were within the normal range of young premenopausal women in the mid-follicular phase, with a proportional dose‒response effect.Conclusions These results on vasomotor symptoms are consistent with the optimal cardiovascular and skeletal benefits observed in KEEPS (TdL estradiol) and ELITE (oral estradiol), corresponding to serum levels of approximately 60 pg/mL.
科研通智能强力驱动
Strongly Powered by AbleSci AI